All Oncology News

Bruce Edgar, PhD, researcher at Huntsman Cancer Institute, has been elected as a member to the National Academy of Sciences.

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.

SCG101 T-cell therapy was safe and induced sustained HBV clearance and antitumor activity in patients with advanced HBV-related hepatocellular carcinoma.

Deena M. Atieh Graham, MD, highlights the current treatment paradigm in ovarian cancer, particularly PARP inhibitors and new ADCs in the space.

New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.

FDA lifts clinical hold on tabelecleucel IND, enabling trial resumption in EBV+ PTLD following HSCT or SOT in relapsed/refractory patients.

In a 3-part series, Evan S. Wu, MD, PhD, will explore key issues surrounding the translatability of Chinese drug development data to a US population.

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

The NCCN guidelines now recommend a naxitamab-based regimen for high-risk neuroblastoma.

The Signatera MRD assay was associated with high levels of sensitivity and specificity in sarcomas.

Neoadjuvant T-DXd plus THP significantly improved pCR rates in HER2+ early breast cancer.

The addition of VCN-01 to gemcitabine and nab-paclitaxel improved survival in newly diagnosed metastatic pancreatic cancer.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Study investigators are aiming to leverage therapy resistance, particularly in patients with solid tumors after receiving available RAS inhibitors.

Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.

Early progression or death within 24 months of first-line treatment was linked to inferior survival in mantle cell lymphoma.

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

The addition of elraglusib to gemcitabine and nab-paclitaxel improved overall survival is first-line metastatic pancreatic cancer.

Hackensack Meridian JFK University Medical Center has expanded its comprehensive cancer care services with the opening of a newly renovated, four-story facility at 80 James Street in Edison, NJ

The FDA has granted fast-track designation to givinostat for the treatment of patients with polycythemia vera.

The European Commission has approved acalabrutinib plus bendamustine and rituximab for previously untreated, transplant-ineligible mantle cell lymphoma.

Shannon Westin, MD, MPH, FACOG, contextualizes data from an exploratory biomarker analysis of the phase 3 DUO-E trial in pMMR recurrent endometrial cancer.

The next-generation ADC ARX788 is under investigation in the phase 2 ACE-Breast-03 trial of patients with T-DXd–pretreated HER2-positive breast cancer.

Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.

The combination of nivolumab and ipilimumab was associated with longer 12-month OS vs standard of care in non–clear cell renal cell carcinoma.

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

ISB 2001 has received fast track designation from the FDA for patients with relapsed or refractory multiple myeloma who received 3 or more prior therapies.